Medicare CED Could Enhance Efficiency Of FDA Post-Approval Studies – CMS Draft Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicare’s coverage with evidence development policy could help enhance the efficiency of research conducted under FDA post-approval requirements, CMS says in a draft guidance on CED released Nov. 29.
You may also be interested in...
Final Medicare Coverage-With-Evidence-Development Guidance Delayed By CMS Staff Cuts
The CMS coverage and analysis group has had to divert its attention from finishing a CED guidance to finalizing proposed changes to the process for awarding Medicare coverage for investigational device trials, primarily due to staff cuts, says Louis Jacques, who heads the group.
Medicare CED Could Enable Expanded Use Of Expedited Drug Approvals, Policy Groups Suggest
Based on stakeholder consultations, former FDA and CMS head Mark McClellan and former CMS official Sean Tunis present a potential upside for biopharma in broader use of Medicare coverage with evidence development. Pfizer executives participate in workshop on coordinating expedited drug approval, CED policies.
Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?
Insurance plans put on notice that CMS is concerned about restrictions on drugs with negotiated prices, but it’s not clear what the agency can or will do about it.